The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)
Authors:
Open Access
- 1 March 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-12
Abstract
To investigate the potential benefits of acarbose therapy on cardiovascular events (CVD) in Type 2 diabetes (T2DM) in an urban community over 10-year follow-up. The study population of Beijing Community Diabetes Study (BCDS) were type 2 diabetes (T2DM) living in 21 communities in Beijing. All patients received comprehensive intervention in accordance with the Chinese guidelines for the prevention and treatment of diabetes. Professors in endocrinology from top tier hospitals regularly visited the communities for consultations, which was a feature of this study. A total of 1797 T2DM in BCDS study had complete screening data, including blood glucose, blood pressure, lipid profiles and acarbose continuous therapy. After 10-year follow-up, the risks of CVD outcomes were assessed according to whether patients had received acarbose therapy or not. All patients were followed-up to assess the long-term effects of the multifactorial interventions. At baseline, compared with the acarbose therapy free in T2DM, there was no significant difference in achieving the joint target control in patients with acarbose therapy. From the beginning of 8th year follow-up, the joint target control rate in patients with acarbose therapy was significantly higher than that of acarbose therapy free. During the 10-year follow-up, a total of 446 endpoint events occurred, including all-cause death, cardiovascular events, cerebrovascular events. The incidences of myocardial infarction (from the 4th year of follow-up) and all-cause death (from the 2nd year of follow-up) in patients who received acarbose therapy were significantly lower than that of acarbose therapy free respectively. In Cox multivariate analyses, there were significant differences in incidences of myocardial infarction and all-cause death between afore two groups during the 10-year follow-up, and the adjusted HRs were 0.50 and 0.52, respectively. After multifactorial interventions, T2DM with acarbose therapy revealed significant reductions of myocardial infarction and all-cause death. The long-term effects of with acarbose therapy on improving joint target control might be one of the main reasons of myocardial infarction and all-cause death reduction.Trial Registration: ChiCTR-TRC-13003978, ChiCTR-OOC-15006090.Keywords
Funding Information
- Beijing Municipal Science Technology Commission (Z151100004015021)
- BRIDGES grant from the International Diabetes Federation (ST12-024)
- a Grant of Special Scientific Research on Capital Health Development (2011-2005-01, 2016-1-2057, 2016-2-2054)
- a Capital Medical Development Foundation of China (2007-1035)
This publication has 26 references indexed in Scilit:
- Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trialThe Lancet Diabetes & Endocrinology, 2014
- Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent–Naive Subjects with Type 2 DiabetesDiabetes Technology & Therapeutics, 2013
- Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluationDiabetes & Vascular Disease Research, 2012
- PREVALENCE AND RISK FACTORS FOR DIABETIC RETINOPATHYRetina, 2012
- Effects of Acarbose Versus Glibenclamide on Glycemic Excursion and Oxidative Stress in Type 2 Diabetic Patients Inadequately Controlled by Metformin: A 24-Week, Randomized, Open-Label, Parallel-Group ComparisonClinical Therapeutics, 2011
- Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: An Asian-Pacific perspective and expert recommendationsDiabetes Research and Clinical Practice, 2011
- Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoringDiabetes/Metabolism Research and Reviews, 2010
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Current and Future Directions of Cardiovascular Risk PredictionThe American Journal of Cardiology, 2006
- Acarbose for the Prevention of Diabetes, Hypertension, and Cardiovascular Disease in Subjects with Impaired Glucose Tolerance: The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (Stop-Niddm) TrialEndocrine Practice, 2006